Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector
20 Junho 2024 - 9:30AM
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the
"Company"), a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced that it has
successfully signed two new major customer accounts within the UK
warehouse and logistics sector within the past three months. These
accounts employ more than 15,000 individuals at more than 70
locations and will adopt INBS’ innovative Intelligent
Fingerprinting Drug Screening System at the majority of their UK
sites.
One account, an award-winning company known for
its innovation in business and specializing in developing and
deploying supply chain solutions, switched to INBS' Intelligent
Fingerprinting Drug Screening System to address the inefficiencies
with its former saliva testing method. The second account had been
using saliva testing in-house for initial screening and confirming
samples with a third-party service. This account was secured
following strong recommendations from two of INBS' existing
customers, demonstrating a growing trust in and awareness of the
Company's unique technology in vital sectors. INBS now provides
both businesses with its simple, reliable and non-invasive testing
solution that promotes operational efficiency and employee
dignity.
Doug Heath, Vice President of Global Sales at
INBS, commented, “These key customer wins, particularly those
through existing customer referrals, show that brand recognition
and product loyalty are on the rise. Our solution is becoming
well-recognized as a highly competitive alternative to traditional
methods and is increasingly selected for its overall cost-savings,
portability and effectiveness in promoting safety and workplace
efficiency. We look forward to working with these new accounts to
ensure they fully leverage our technology to enhance their business
operations.”
INBS' first-of-its-kind solution uses
fingerprint sweat to provide a quick, hygienic, and easy-to-use
method for drug testing, delivering results in just minutes. This
unique approach tests for common drugs of abuse, including cocaine,
cannabis, methamphetamine, and opiates.
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is
a medical technology company delivering innovative, rapid,
non-invasive testing solutions. The Company believes that its
Intelligent Fingerprinting Drug Screening System will revolutionize
portable testing through fingerprint sweat analysis, which has the
potential for broader applications in additional fields. Designed
as a hygienic and cost-effective system, the test screens for
recent use of drugs commonly found in the workplace, including
opiates, cocaine, methamphetamine, and cannabis. With sample
collection in seconds and results in under ten minutes, this
technology would be a valuable tool for employers in
safety-critical industries. Additionally, the Company's biosensor
platform has the potential to test for various indications, ranging
from immunological conditions to communicable diseases. The
Company's current customer segments include construction,
manufacturing and engineering, transport and logistics firms, drug
treatment organizations, and coroners.
For more information,
visit: http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.'s ability to successfully develop and commercialize
its drug and diagnostic tests, realize commercial benefit from its
partnerships and collaborations, and secure regulatory approvals,
among others. Although Intelligent Bio Solutions Inc. believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions Inc. has
attempted to identify forward-looking statements by terminology,
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, included in Intelligent Bio Solutions' public filings
filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company Contact:Intelligent Bio Solutions
Inc. info@ibs.incLinkedIn | Twitter
Investor & Media Contact:Valter Pinto,
Managing DirectorKCSA Strategic CommunicationsPH: (212)
896-1254INBS@kcsa.com
Intelligent Bio Solutions (NASDAQ:INBS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Intelligent Bio Solutions (NASDAQ:INBS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024